Advertisement

Archives of Orthopaedic and Trauma Surgery

, Volume 128, Issue 8, pp 815–823 | Cite as

What is the evidence for viscosupplementation in the treatment of patients with hip osteoarthritis? Systematic review of the literature

  • Michel P. J. van den Bekerom
  • Bas Lamme
  • An Sermon
  • Michiel MulierEmail author
Orthopaedic Surgery

Abstract

Introduction

Osteoarthritis (OA) is a disease of the synovial joints and is the most common cause of chronic pain in the elderly. One of the treatment modalities for OA of the hip is viscosupplementation (VS). Today there are several different formulations of viscosupplements produced by different manufactures of different molecular weights. The objective of this review is to asses the efficacy of VS treatment of hip OA osteoarthritis in the current literature.

Material and methods

The following databases were searched: Medline (period 1966 to November 2006), Cochrane Database of Systematic Reviews (1988 to November 2006), Cochrane Clinical Trial Register (1988 to November 2006), Database of Abstracts on Reviews and Effectiveness, Current Controlled Trials, National Research Register and Embase (January 1988 to November 2006). The search terms [osteoarthritis, hip (joint), viscosupplementation, hyaluronic acid, hyaluronan, sodium hyaluronate and trade names] were applied to identify all studies relating to the use of VS therapy for OA of the hip joint.

Results

Sixteen articles concerning the efficacy of a total of 509 patients undergoing VS treatment for hip OA were included. Twelve European studies, three Turkish studies and one American study with Levels of Evidence ranging from I to IV evaluated the following products: Hylan G-F 20, Hyalgan®, Ostenil®, Durolane®, Fermatron® and Orthovisc®. Heterogeneity of included studies did not allow pooled analysis of data.

Discussion

Despite the relatively low Level of Evidence of the included studies, VS performed under fluoroscopic or ultrasound guidance seems an effective treatment and may be an alternative treatment of hip OA. Intra-articular injection of (derivatives of) HA into the hip joint appears to be safe and well tolerated. However, VS cannot be recommended as standard therapy in hip OA for wider populations, and therefore the indications remain a highly individualised matter.

Keywords

Review Osteoarthritis Hip joint Viscosupplementation Hyaluronan Hyaluronic acid 

Abbreviations

AAOS

American Association Orthopaedic Surgeons

CEBM

Centre for Evidence Based Medicine

HA

Hyaluronic acid

IA

Intra-articular

MDa

Million Daltons

MW

Molecular weight

NASHA

Non-animal stabilised hyaluronic acid

NSAID

Non-steroidal anti inflammatory drug

OA

Osteo-arthritis

PAS

Pain analogue scale

RCT

Randomised controlled trial

THA

Total hip arthroplasty

VAS

Visual analogue scale

VS

Viscosupplementation

WOMAC

Western Ontario and McMaster Universities osteoarthritis index

OMERACT

Outcome measures in rheumatology

Notes

Acknowledgments

The authors are grateful to A. van Horssen for collecting the required articles and to N. Vandenhecke for her help in the preparation of this manuscript. No benefits in any form have been received or will be received from a commercial party related directly or indirectly to the subject of this review. No sources of funding were received to assist in this review. The authors have no conflicts of interest that are directly relevant to this study.

References

  1. 1.
    Adams ME (1993) Viscosupplementation: a treatment for osteoarthritis. J Rheum 20(suppl 39):2Google Scholar
  2. 2.
    American Academy of Orthopaedic Surgeons (AAOS), Council of Musculoskeletal Specialty Societies (COMSS) in Tarpon Springs, Florida, in April 1994Google Scholar
  3. 3.
    Balzas E (1982) The viscoelastic properties of synovial fluid and the special role of hyaluronic acid. In: Heflet A (ed) Disorders of the knee, 2nd edn. JB Lippencott, Philadelphia, pp 61–74Google Scholar
  4. 4.
    Bellamy N, Buchanan WW, Goldsmith CH et al (1988) Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 15:1833–1840PubMedGoogle Scholar
  5. 5.
    Bellamy N, Campbell J, Robinson V et al (2006) Viscosupplementation for the treatment of osteoarthritis of the knee. In: The cochrane database of systematic reviews 19(2), Art No.: CD005321Google Scholar
  6. 6.
    Bellamy N, Kirwan J, Boers M et al (1997) Recommendations for a core set of outcome measures for future phase III clinical trials in knee, hip, and hand osteoarthritis. Consensus development at OMERACT III. J Rheumatol 24(4):799–802PubMedGoogle Scholar
  7. 7.
    Berg P, Olsson U (2004) Intra articular injection of non-animal stabilised hyaluronic acid (NASHA) for osteoarthritis of the hip: a pilot study. Clin Exp Rheumatol 22:300–306PubMedGoogle Scholar
  8. 8.
    Bertolami C, Gay T, Clark G et al (1993) Use of sodium hyaluronate in treating temporo-mandibular joint disorders: a randomized double blind, placebo controlled clinical trial. J Oral Maxillofacial Surg 51:232–242CrossRefGoogle Scholar
  9. 9.
    Bragantini A, Molinaroli F (1994) A pilot clinical evaluation of the treatment of hip osteoarthritis with hyaluronic acid. Clin Ther Res 55:3319–3330Google Scholar
  10. 10.
    Brocq O, Tran G, Breuil V et al (2002) Hip osteoarthritis: short term efficacy and safety of viscosupplementation by hylan G-F 20. An open label study in 22 patients. Joint Bone Spine 69(4):388–391PubMedCrossRefGoogle Scholar
  11. 11.
    Caglar-Yagci H, Unsal S, Yagci I et al (2005) Safety and efficacy of ultrasound-guided intra-articular hylan G-F 20 injection in osteoarthritis of the hip: a pilot study. Rheumatol Int 25(5):341–344PubMedCrossRefGoogle Scholar
  12. 12.
    Chazerain P, Rolland D, Cordonnier C (1999) Septic hip arthritis after multiple injections into the joint of hyaluronate and glucocorticoid. Rev Rhum (Engl Ed) 6:436Google Scholar
  13. 13.
    Conrozier T, Bertin P, Mathieu P et al (2003) Intra-articular injections of hylan G-F 20 in patients with symptomatic hip osteoarthritis: an open label multicentre, pilot study. Clin Exp Rheumatol 21(5):605–610PubMedGoogle Scholar
  14. 14.
    Conrozier T, Vignon E (2005) Is there evidence to support the inclusion of viscosupplementation in the treatment paradigm for patients with hip osteoarthritis? Clin Exp Rheumatol 23:711–716PubMedGoogle Scholar
  15. 15.
    De Nies F, Fiddler MW (1997) Visual analog scale for the assessment of total hip arthroplasty. J Arthroplasty 12(4):416–419PubMedCrossRefGoogle Scholar
  16. 16.
    Egsmose C, Lund B, Bach Andersen R (1984) Hip joint distension in osteoarthrosis. A triple-blind controlled study comparing the effect of intra-articular indoprofen with placebo. Scand J Rheumatol 13:238–242PubMedCrossRefGoogle Scholar
  17. 17.
    Felson DT (1988) Epidemiology of hip and knee osteoarthritis. Epidemiol Rev 10:1–18PubMedGoogle Scholar
  18. 18.
    Fletcher B, Sackett DL (1979) Canadian task force on the periodic health examination: the Periodic Health Examination. CMAJ 121:1193–1254Google Scholar
  19. 19.
    Harris WH (1969) Traumatic arthritis of the hip after dislocation and acetabular fractures: treatment by mold arthroplasty. J Bone Joint Surg Am 51-A:737–755Google Scholar
  20. 20.
    Hochberg MC, Altman RD, Brandt KD et al (1995) Guidelines for the medical management of osteoarthritis. Part I. Osteoarthritis of the hip. American College of Rheumatology. Arthritis Rheum 38:1535–1540PubMedCrossRefGoogle Scholar
  21. 21.
    Itokazu M, Matsunaga T (1995) Clinical evaluation of high molecular weight sodium hyaluronate for the treatment of patients with peri-arthritis of the shoulder. Clin Ther 17(5):946–955PubMedCrossRefGoogle Scholar
  22. 22.
    Jadad AR, Moore A, Carroll D et al (1996) Assessing the quality of reports of randomised controlled trials: is blinding necessary? Contr Clin Trials 17:1–12CrossRefGoogle Scholar
  23. 23.
    Kopp S, Akerman S, Nilner M et al (1991) Short term effects of intra-articular sodium hyaluronate, glucocorticoid, and saline injections on rheumatoid arthritis of the temporo-mandibular joint. J Craniomandibular Dis Facial oral Pain 5(4):231–238Google Scholar
  24. 24.
    Lawrence RC, Helmick CG, Arnett FC et al (1998) Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 41:778–799PubMedCrossRefGoogle Scholar
  25. 25.
    Leardini G, Perbellini A, Franceschini M et al (1988) Intra-articular injections of hyaluronate acid in the treatment of the painful shoulder. Clin Ther 10:521–525PubMedGoogle Scholar
  26. 26.
    Lequesne M, Mery C, Samson M et al (1987) Indexes of severity for osteoarthritis of the hip and knee. Indexes of severity for osteoarthritis of the hip and knee. Validation and value in comparison with other assessment tests. Scand J Rheumatol Suppl 65:85–89PubMedCrossRefGoogle Scholar
  27. 27.
    Ling SM, Bathon JM (1998) Osteoarthritis in older adults. J Am Geriatr Soc 46:216–225PubMedGoogle Scholar
  28. 28.
    Lo GH, LaValley M, McAlindon T et al (2003) Intra-articular hyaluronic acid in treatment of knee osteoarthritis—a meta-analysis. JAMA 290(23):3115–3121PubMedCrossRefGoogle Scholar
  29. 29.
    March LM, Bachmeier CJ (1997) Economics of osteoarthritis: a global perspective. Baillieres Clin Rheumatol 11:817–834PubMedCrossRefGoogle Scholar
  30. 30.
    Marshall K (1997) The current status of hylan therapy for the treatment of osteoarthritis. Todays ther Trends 15:99–108Google Scholar
  31. 31.
    Migliore A, Martin LSM, Alimonte A (2003) Efficacy and safety of viscosupplementation by ultra-sound guided intra-articular injection in osteoarthritis of the hip. Osteoarthritis Cartil 11(4):305–306CrossRefGoogle Scholar
  32. 32.
    Migliore A, Tormenta S, Massafra U et al (2005) Repeated ultrasound-guided intra-articular injections of 40 mg of Hyalgan may be useful in symptomatic relief of hip osteoarthritis. Osteoarthritis Cartil 13(12):1126–1127CrossRefGoogle Scholar
  33. 33.
    Migliore A, Tormenta S, Martin LS et al (2005) Open pilot study of ultrasound guided intra-articular injection of Hylan G-F 20 (Synvisc) in the treatment of symptomatic hip osteoarthritis. Clin Rheumatol 24(3):285–289PubMedCrossRefGoogle Scholar
  34. 34.
    Migliore A, Tormenta S, Martin Martin LS et al (2006) The symptomatic effects of intra-articular administration of hylan G-F 20 on osteoarthritis of the hip: clinical data of 6 months follow-up. Clin Rheumatol 25(3):389–393PubMedCrossRefGoogle Scholar
  35. 35.
    Migliore A, Tormenta S, Martin Martin LS et al (2004) Safety profile of 185 ultrasound-guided intra-articular injections for treatment of rheumatic diseases of the hip. Reumatismo 56(2):104–109PubMedGoogle Scholar
  36. 36.
    Migliore A, Tormenta S, Massafra U et al (2006) 18 month observational study on efficacy of intraarticular hyaluronic acid (Hylan G-F 20) injections under ultrasound guidance in hip osteoarthritis. Reumatismo 58(1):39–49PubMedGoogle Scholar
  37. 37.
    Migliore A, Tormenta S, Valenta C et al (2005) Intra-articular treatment with hylan G-F 20 under ultrasound guidance in hip osteoarthritis. Clinical results after 12 months follow-up. Reumatismo 57(1):36–43PubMedGoogle Scholar
  38. 38.
    Pourbagher MA, Ozalay M, Pourbagher A (2005) Accuracy and outcome of sonographically guided intra-articular sodium hyaluronate injections in patients with osteoarthritis of the hip. J Ultrasound Med 24:1391–1395PubMedGoogle Scholar
  39. 39.
    Qvistgaard E, Christensen R, Torp-Pedersen S et al (2006) Intra-articular treatment of hip osteoarthritis: a randomised trial of hyaluronic acid, corticosteroid, and isotonic saline. Osteoarthritis Cartil 14(2):163–170CrossRefGoogle Scholar
  40. 40.
    Schulz KF, Chalmers I, Grimes DA et al (1994) Assessing the quality of randomisation from reports of controlled trials published in obstetrics and gynaecology journals. JAMA 272:125–128PubMedCrossRefGoogle Scholar
  41. 41.
    Tepper S, Hochberg MC (1993) Factors associated with hip osteoarthritis: Data from the first National Health and Nutrition Examination Survey (NHANES-1). Am J Epidemiol 137:1081–1088PubMedGoogle Scholar
  42. 42.
    Thomas E, Peat G, Hill S et al (2004) The North Staffordshire Osteoarthritis Project-NorStop: prospective 3 year study of the epidemiology and management of clinical osteoarthritis in a general population of older adults. BMC Musculoskelet Disord 5:2PubMedCrossRefGoogle Scholar
  43. 43.
    Tikiz C, Unlu Z, Sener A et al (2005) Comparison of the efficacy of lower and higher molecular weight viscosupplementation in treatment of hip osteoarthritis. Clin Rheumatol 24(3):244–250PubMedCrossRefGoogle Scholar
  44. 44.
    Vad VB, Sakalkale D, Sculco TP et al (2003) Role of hylan G-F 20 in treatment of osteoarthritis of the hip joint. Arch Phys Med Rehabil 84(8):1224–1226PubMedCrossRefGoogle Scholar
  45. 45.
    van den Bekerom MPJ, Mylle G, Rys B et al (2006) Viscosupplementation in symptomatic severe hip-osteoarthritis: A review of the literature and report on 60 patients. Acta Orthop Belg 72:560–566Google Scholar
  46. 46.
    Verhagen AP, de Vet HC, de Bie RA et al (1998) Balneotherapy and quality assessment: interobserver reliability of the Maastricht criteria list and the need for blinded quality assessment. J Clin Epid 51:335–341CrossRefGoogle Scholar
  47. 47.
    Weiss C, Band P (1995) Musculoskeletal applications of hyaluron and hylan. Potential uses in the foot and ankle. Clin Pod Med Surg 12(3):497–517Google Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  • Michel P. J. van den Bekerom
    • 1
  • Bas Lamme
    • 2
  • An Sermon
    • 3
  • Michiel Mulier
    • 4
    Email author
  1. 1.Department of Orthopaedic SurgeryA.M.CAmsterdamThe Netherlands
  2. 2.Department of SurgeryA.M.CAmsterdamThe Netherlands
  3. 3.Department of TraumatologyU.Z. GasthuisbergLeuvenBelgium
  4. 4.Department of Orthopaedic SurgeryU.Z. Pellenberg, K.U.LeuvenPellenbergBelgium

Personalised recommendations